Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly, idempotent, openWorld and non-destructive, so the safety profile is covered. The description adds genuinely useful context the annotations lack: the cost model (free within the daily allowance, then $0.002 USDC per call via x402), which informs call budgeting. It does not describe return shape, but an output schema exists to carry that.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

Two compact sentences that are front-loaded with the capability before the pricing detail. No filler; the only mild criticism is that the pricing clause competes for attention with the functional statement.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a single-parameter, read-only lookup with an output schema and rich annotations, the description supplies what the structured fields cannot: the conceptual scope of the results and the cost/quota behavior. What it omits, sibling differentiation, is useful but not essential to invoking it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Only one parameter (rxcui) with 100% schema description coverage, so the schema fully documents the input. The description says 'related to an RxCUI' but adds no syntax, format, or validity detail beyond the schema, making the baseline 3 appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

States a clear resource (related concepts for an RxCUI) and enumerates the returned categories (ingredients, brand names, dose forms, clinical/branded drugs), which is more than a tautology. It does not, however, explicitly distinguish itself from close siblings like rxnorm__drugs or rxnorm__properties, which also surface drug concepts.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

There is no guidance on when to choose this tool over rxnorm__drugs, rxnorm__properties, or rxnorm__approximate. The pricing sentence describes cost, not usage conditions, so the agent must infer selection criteria from the name alone.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.